Cite
Hiltunen J, Parmanne P, Sokka T, et al. Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis. Rheumatol Int. 2021;doi: 10.1007/s00296-021-04955-8.
Hiltunen, J., Parmanne, P., Sokka, T., Lamberg, T., Isomäki, P., Kaipiainen-Seppänen, O., Peltomaa, R., Uutela, T., Pirilä, L., Taimen, K., Kauppi, M. J., Yli-Kerttula, T., Tuompo, R., Relas, H., Kortelainen, S., Paalanen, K., Asikainen, J., Ekman, P., Santisteban, A., Vidqvist, K. L., Tadesse, K., Romu, M., Borodina, J., Elfving, P., Valleala, H., Leirisalo-Repo, M., Rantalaiho, V., Kautiainen, H., Jokiranta, T. S., Eklund, K. K. (2021). Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis. Rheumatology international, . https://doi.org/10.1007/s00296-021-04955-8
Hiltunen, J, et al. "Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis." Rheumatology international vol. (2021). doi: https://doi.org/10.1007/s00296-021-04955-8
Hiltunen J, Parmanne P, Sokka T, Lamberg T, Isomäki P, Kaipiainen-Seppänen O, Peltomaa R, Uutela T, Pirilä L, Taimen K, Kauppi MJ, Yli-Kerttula T, Tuompo R, Relas H, Kortelainen S, Paalanen K, Asikainen J, Ekman P, Santisteban A, Vidqvist KL, Tadesse K, Romu M, Borodina J, Elfving P, Valleala H, Leirisalo-Repo M, Rantalaiho V, Kautiainen H, Jokiranta TS, Eklund KK. Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis. Rheumatol Int. 2021 Aug 06; doi: 10.1007/s00296-021-04955-8. Epub 2021 Aug 06. PMID: 34357455.
Copy
Download .nbib